Arcutis Biotherapeutics ARQT
$26.36 −$0.81 (-2.98%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $26.40 +0.15%
Open$26.91
Prev close$27.17
Day range$26.29 – $27.47
Volume1.29M
Market cap$3.33B
P/E (TTM)119.8
Dividend yield–
ARQT Stock News
Headlines matching Arcutis Biotherapeutics or the ARQT ticker, most recent first.
- Form 144 | Arcutis Biotherapeutics(ARQT.US) Insider Proposes to Sell 8.55 Million in Common Stocks
- A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $40
- H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34
- Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)
- Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36
- A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)
- Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)
- H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
- Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $35 Negative
- A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37
No comments yet — be the first to weigh in on ARQT.
Sign in to join the discussion.